Venetoclax, an oral BCL‐2 protein inhibitor, has shown promising results in combination with hypomethylating agents or low‐dose cytarabine in older patients with AML.[11, 32] Various clinical trials have investigated the combination of venetoclax with other targeted therapies for specific AML subgroups, such as IDH inhibitors for IDH1/2‐mutant AML[33] and FLT3 inhibitors for FLT3‐mutant AML.[10, 34]. Here, BCL2 is linked to acute myeloid leukemia.